메뉴 건너뛰기




Volumn 68, Issue 4, 2011, Pages 473-479

Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CELL MARKER; MITOXANTRONE;

EID: 79953867234     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.322     Document Type: Article
Times cited : (87)

References (30)
  • 3
    • 77950881518 scopus 로고    scopus 로고
    • Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis
    • Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol. 2010;17(5):672-676.
    • (2010) Eur J Neurol , vol.17 , Issue.5 , pp. 672-676
    • Uzawa, A.1    Mori, M.2    Hayakawa, S.3    Masuda, S.4    Kuwabara, S.5
  • 4
    • 75649107856 scopus 로고    scopus 로고
    • B-cell activating factor of the TNF family is upregulated in neuromyelitis optica
    • Okada K, Matsushita T, Kira J, Tsuji S. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology. 2010;74(2):177-178.
    • (2010) Neurology , vol.74 , Issue.2 , pp. 177-178
    • Okada, K.1    Matsushita, T.2    Kira, J.3    Tsuji, S.4
  • 5
    • 16844366404 scopus 로고    scopus 로고
    • An open label study of the effects of rituximab in neuromyelitis optica
    • Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272.
    • (2005) Neurology , vol.64 , Issue.7 , pp. 1270-1272
    • Cree, B.A.1    Lamb, S.2    Morgan, K.3    Chen, A.4    Waubant, E.5    Genain, C.6
  • 6
    • 0031665071 scopus 로고    scopus 로고
    • Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine
    • Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219-1220. (Pubitemid 28473439)
    • (1998) Neurology , vol.51 , Issue.4 , pp. 1219-1220
    • Mandler, R.N.1    Ahmed, W.2    Dencoff, J.E.3
  • 8
    • 55949127730 scopus 로고    scopus 로고
    • Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients
    • Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-1448.
    • (2008) Arch Neurol , vol.65 , Issue.11 , pp. 1443-1448
    • Jacob, A.1    Weinshenker, B.G.2    Violich, I.3
  • 9
    • 70349150578 scopus 로고    scopus 로고
    • Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients
    • Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128-1133.
    • (2009) Arch Neurol , vol.66 , Issue.9 , pp. 1128-1133
    • Jacob, A.1    Matiello, M.2    Weinshenker, B.G.3
  • 12
    • 11244349904 scopus 로고    scopus 로고
    • Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients
    • DOI 10.1111/j.1365-2249.2005.02653.x
    • Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005;139(1):152-158. (Pubitemid 40066141)
    • (2005) Clinical and Experimental Immunology , vol.139 , Issue.1 , pp. 152-158
    • Chan, A.1    Weilbach, F.X.2    Toyka, K.V.3    Gold, R.4
  • 14
    • 33745334334 scopus 로고    scopus 로고
    • Revised diagnostic criteria for neuromyelitis optica
    • DOI 10.1212/01.wnl.0000216139.44259.74, PII 0000611420060523000008
    • Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489. (Pubitemid 43958540)
    • (2006) Neurology , vol.66 , Issue.10 , pp. 1485-1489
    • Wingerchuk, D.M.1    Lennon, V.A.2    Pittock, S.J.3    Lucchinetti, C.F.4    Weinshenker, B.G.5
  • 15
    • 0026018422 scopus 로고
    • DNA strand breakage by peroxidase-activated mitoxantrone
    • Fisher GR, Patterson LH. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol. 1991;43(1):65-68.
    • (1991) J Pharm Pharmacol , vol.43 , Issue.1 , pp. 65-68
    • Fisher, G.R.1    Patterson, L.H.2
  • 16
    • 0029121860 scopus 로고
    • Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza-and 2-aza-oxide- anthracenedione derivatives
    • De Isabella P, Palumbo M, Sissi C, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza-and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol. 1995;48(1):30-38.
    • (1995) Mol Pharmacol , vol.48 , Issue.1 , pp. 30-38
    • De Isabella, P.1    Palumbo, M.2    Sissi, C.3
  • 17
    • 0027333102 scopus 로고
    • Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts
    • Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis. 1993;14(11):2341-2351. (Pubitemid 23335192)
    • (1993) Carcinogenesis , vol.14 , Issue.11 , pp. 2341-2351
    • Thielmann, H.W.1    Popanda, O.2    Gersbach, H.3    Gilberg, F.4
  • 18
    • 33751010179 scopus 로고    scopus 로고
    • Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: A possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis
    • DOI 10.1001/archneur.63.11.1572
    • Kopadze T, Dehmel T, Hartung HP, Stüve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol. 2006;63(11):1572-1578. (Pubitemid 44748799)
    • (2006) Archives of Neurology , vol.63 , Issue.11 , pp. 1572-1578
    • Kopadze, T.1    Dehmel, T.2    Hartung, H.-P.3    Stuve, O.4    Kieseier, B.C.5
  • 19
    • 10944231932 scopus 로고    scopus 로고
    • Mechanism of action of mitoxantrone
    • Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12)(suppl 6): S15-S18. (Pubitemid 40019273)
    • (2004) Neurology , vol.63 , Issue.12 SUPPL. 6
    • Fox, E.J.1
  • 20
    • 0022450390 scopus 로고
    • Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function
    • Fidler JM, DeJoy SQ, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone I: suppression of B lymphocyte function. J Immunol. 1986;137(2):727-732. (Pubitemid 16045109)
    • (1986) Journal of Immunology , vol.137 , Issue.2 , pp. 727-732
    • Fidler, J.M.1    DeJoy, S.Q.2    Gibbons Jr., J.J.3
  • 22
    • 70349411720 scopus 로고    scopus 로고
    • Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting
    • Singhal BS, Geeta S, Hundalani SG, Menon S. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Neurol India. 2009;57(4):418-423.
    • (2009) Neurol India , vol.57 , Issue.4 , pp. 418-423
    • Singhal, B.S.1    Geeta, S.2    Hundalani, S.G.3    Menon, S.4
  • 23
    • 10944233139 scopus 로고    scopus 로고
    • Mitoxantrone treatment of multiple sclerosis: Safety considerations
    • Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology. 2004;63(12)(suppl 6):S28-S32. (Pubitemid 40019276)
    • (2004) Neurology , vol.63 , Issue.12 SUPPL. 6
    • Cohen, B.A.1    Mikol, D.D.2
  • 24
    • 77951828930 scopus 로고    scopus 로고
    • Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    • Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    • Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463-1470.
    • (2010) Neurology , vol.74 , Issue.18 , pp. 1463-1470
    • Marriott, J.J.1    Miyasaki, J.M.2    Gronseth, G.3    O'Connor, P.W.4
  • 25
    • 63449128972 scopus 로고    scopus 로고
    • Therapy-related acute leukaemia with mitoxantrone: What is the risk and can we minimise it?
    • Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler. 2009;15(4):505-508.
    • (2009) Mult Scler , vol.15 , Issue.4 , pp. 505-508
    • Ellis, R.1    Boggild, M.2
  • 26
    • 0038579530 scopus 로고    scopus 로고
    • Effect of regression to the mean on decision making in health care
    • Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ. 2003;326(7398):1083-1084. (Pubitemid 36629731)
    • (2003) British Medical Journal , vol.326 , Issue.7398 , pp. 1083-1084
    • Morton, V.1    Torgerson, D.J.2
  • 27
    • 37749016994 scopus 로고    scopus 로고
    • Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: Treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
    • Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79(1):52-56.
    • (2008) J Neurol Neurosurg Psychiatry , vol.79 , Issue.1 , pp. 52-56
    • Le Page, E.1    Leray, E.2    Taurin, G.3
  • 28
    • 59249089860 scopus 로고    scopus 로고
    • Concepts of induction and escalation therapy in multiple sclerosis
    • Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(suppl 1):S42-S45.
    • (2009) J Neurol Sci , vol.277 , Issue.SUPPL. 1
    • Rieckmann, P.1
  • 29
    • 59249103269 scopus 로고    scopus 로고
    • Immunosuppression followed by immunomodulation
    • Boggild M. Immunosuppression followed by immunomodulation. J Neurol Sci. 2009;277(suppl 1):S50-S54.
    • (2009) J Neurol Sci , vol.277 , Issue.SUPPL. 1
    • Boggild, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.